Published in Alzheimers Dement on April 03, 2013
Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. J Neurol Neurosurg Psychiatry (2013) 0.94
Primary progressive aphasia and apraxia of speech. Semin Neurol (2013) 0.76
Classification of primary progressive aphasia and its variants. Neurology (2011) 11.82
Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol (2004) 7.07
Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol (2008) 4.15
Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol (2008) 3.99
Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology (2008) 3.76
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Prevalence and severity of microbleeds in a memory clinic setting. Neurology (2006) 2.29
FLAIR histogram segmentation for measurement of leukoaraiosis volume. J Magn Reson Imaging (2001) 2.24
Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRI. Brain (2004) 2.07
Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol (2008) 2.03
Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol (2010) 1.78
Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke (2009) 1.57
Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord (2006) 1.26
Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol (2005) 1.26
An empirically derived short form of the Boston naming test. Arch Clin Neuropsychol (1999) 1.24
Cerebral amyloid angiopathy in the elderly. J Am Geriatr Soc (1981) 1.13
Cerebral microbleeds in Alzheimer's disease. J Neurol (2003) 1.07
MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population. Stroke (2008) 1.03
Subclinical brain hemorrhages in Alzheimer's disease: evaluation by magnetic resonance T2*-weighted images. Ann N Y Acad Sci (2002) 0.89
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol (2014) 1.89
An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun (2016) 1.45
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement (2015) 1.17
Estimating long-term multivariate progression from short-term data. Alzheimers Dement (2014) 0.99
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement (2015) 0.98
[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol (2016) 0.95
Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging (2014) 0.89
Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement (2016) 0.89
Mapping ventricular expansion onto cortical gray matter in older adults. Neurobiol Aging (2014) 0.87
The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimers Dement (2014) 0.87
Seemingly unrelated regression empowers detection of network failure in dementia. Neurobiol Aging (2014) 0.86
Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. Neurobiol Aging (2014) 0.85
Performance of the CogState computerized battery in the Mayo Clinic Study on Aging. Alzheimers Dement (2015) 0.83
Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat Disord (2014) 0.82
Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement (2016) 0.82
APOE ε4 influences β-amyloid deposition in primary progressive aphasia and speech apraxia. Alzheimers Dement (2014) 0.81
Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. Neurobiol Aging (2013) 0.81
Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. Neuroimage (2015) 0.81
Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. Cortex (2015) 0.80
Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimers Dement (2014) 0.80
The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism Relat Disord (2013) 0.80
Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort. Alzheimers Dement (2015) 0.80
Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimers Dement (2016) 0.80
Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther (2016) 0.79
Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol Aging (2014) 0.79
Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiol Aging (2014) 0.79
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimers Dement (2015) 0.79
FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. J Alzheimers Dis (2016) 0.78
Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Med (2016) 0.77
Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism Relat Disord (2015) 0.77
Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition. J Alzheimers Dis (2016) 0.77
Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity. J Alzheimers Dis (2016) 0.77
Alzheimer's disease: The next frontier-Special Report 2017. Alzheimers Dement (2017) 0.76
Massachusetts Alzheimer's Disease Research Center: Progress and challenges. Alzheimers Dement (2015) 0.76
Microbleeds in atypical presentations of Alzheimer's disease: a comparison to dementia of the Alzheimer's type. J Alzheimers Dis (2015) 0.76
RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiol Aging (2016) 0.76
White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiol Aging (2015) 0.76
Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging (2017) 0.75
Life-course blood pressure in relation to brain volumes. Alzheimers Dement (2016) 0.75
Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement (Amst) (2016) 0.75
Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. Alzheimers Dement (Amst) (2016) 0.75
MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimers Dement (2016) 0.75
A robust biomarker of large-scale network failure in Alzheimer's disease. Alzheimers Dement (Amst) (2017) 0.75
Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. Neuroimage Clin (2016) 0.75
Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. Parkinsonism Relat Disord (2016) 0.75
Tracking the development of agrammatic aphasia: A tensor-based morphometry study. Cortex (2016) 0.75
An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Dement (2016) 0.75
Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. Brain (2017) 0.75
On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther (2017) 0.75
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol (2017) 0.75
First PET Imaging Studies With 63Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease. Mol Imaging (2016) 0.75
Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain (2019) 0.75
Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study of Aging. J Alzheimers Dis (2017) 0.75
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy. Alzheimers Dement (N Y) (2017) 0.75
Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. J Alzheimers Dis (2015) 0.75
Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain (2017) 0.75
Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. J Alzheimers Dis (2016) 0.75
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain (2019) 0.75
Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial MRI study. Alzheimers Dement (2017) 0.75
Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report. Alzheimers Dement (N Y) (2017) 0.75
Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurol (2017) 0.75
Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. Brain Lang (2019) 0.75
White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiol Aging (2017) 0.75